

# Francesco Lanza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4880186/publications.pdf>

Version: 2024-02-01

103  
papers

3,131  
citations

201674

27  
h-index

182427

51  
g-index

105  
all docs

105  
docs citations

105  
times ranked

5216  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	4.6	430
2	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , 2019, 54, 1525-1552.	2.4	218
3	The Reliability and Specificity of c-kit for the Diagnosis of Acute Myeloid Leukemias and Undifferentiated Leukemias. <i>Blood</i> , 1998, 92, 596-599.	1.4	181
4	Clinical manifestation of myeloperoxidase deficiency. <i>Journal of Molecular Medicine</i> , 1998, 76, 676-681.	3.9	161
5	Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 865-872.	2.4	151
6	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	1.4	148
7	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
8	Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes. <i>American Journal of Pathology</i> , 2005, 166, 557-563.	3.8	89
9	A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 225-230.	1.5	88
10	Structural and functional features of the CD34 antigen: an update. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2001, 15, 1-13.	0.7	80
11	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	2.5	56
12	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. <i>Haematologica</i> , 2012, 97, 1722-1730.	3.5	44
13	Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102794.	1.0	43
14	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 314-317.	2.0	42
15	CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults. <i>Cancers</i> , 2020, 12, 303.	3.7	42
16	Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 201-211.	1.5	40
17	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	1.6	39
18	Breast cancer circulating biomarkers: advantages, drawbacks, and new insights. <i>Tumor Biology</i> , 2015, 36, 6653-6665.	1.8	38

#	ARTICLE	IF	CITATIONS
19	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	2.4	36
20	Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells. , 1997, 30, 134-144.		35
21	Essential requirements for setting up a stem cell processing laboratory. <i>Bone Marrow Transplantation</i> , 2014, 49, 1098-1105.	2.4	35
22	Development of adaptive immune effector therapies in solid tumors. <i>Annals of Oncology</i> , 2019, 30, 1740-1750.	1.2	35
23	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	2.4	32
24	Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. <i>Haematologica</i> , 2006, 91, 364-8.	3.5	32
25	Neutrophils from Patients with Myelodysplastic Syndromes: Relationship between Impairment of Granular Contents, Complement Receptors, Functional Activities and Disease Status. <i>Leukemia and Lymphoma</i> , 1994, 13, 471-477.	1.3	31
26	Role of p53 in leukemogenesis of chronic myeloid leukemia. <i>Stem Cells</i> , 1995, 13, 445-452.	3.2	30
27	CD34+ cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2001, 29, 1484-1493.	0.4	29
28	CXCR4pos circulating progenitor cells coexpressing monocytic and endothelial markers correlating with fibrotic clinical features are present in the peripheral blood of patients affected by systemic sclerosis. <i>Haematologica</i> , 2008, 93, 1233-1237.	3.5	29
29	A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential. <i>Cytotherapy</i> , 2011, 13, 523-527.	0.7	28
30	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018, 53, 461-473.	2.4	28
31	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <i>Blood Cancer Journal</i> , 2020, 10, 96.	6.2	28
32	Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients. <i>British Journal of Haematology</i> , 2020, 190, e27-e29.	2.5	28
33	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	5.2	28
34	Cytogenetic aspects of B-cell chronic lymphocytic leukemia: Their correlation with clinical stage and different polyclonal mitogens. <i>Cancer Genetics and Cytogenetics</i> , 1987, 26, 75-84.	1.0	27
35	Individual Quality Assessment of Autografting by Probability Estimation for Clinical Endpoints: A Prospective Validation Study from the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1670-1676.	2.0	26
36	Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program. <i>Bone Marrow Transplantation</i> , 2012, 47, 15-17.	2.4	21

#	ARTICLE	IF	CITATIONS
37	Monoclonal origin of B cells producing k $\lambda$ and k $\lambda$ immunoglobulin light chains in a patient with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 1987, 11, 1093-1098.	0.8	20
38	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1211-1219.	4.1	20
39	Modulation of cell kinetics and cell cycle status by treating CD34+chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides. <i>British Journal of Haematology</i> , 1995, 90, 8-14.	2.5	19
40	Increased myeloperoxidase index and large unstained cell values can predict the neutropenia phase of cancer patients treated with standard dose chemotherapy. <i>Cytometry</i> , 2001, 46, 92-97.	1.8	19
41	Assessment of distribution of CD34 epitope classes in fresh and cryopreserved peripheral blood progenitor cells and acute myeloid leukemic blasts. <i>Haematologica</i> , 1999, 84, 969-77.	3.5	19
42	In vitro evaluation of bone marrow angiogenesis in myelodysplastic syndromes: a morphological and functional approach. <i>Leukemia Research</i> , 2004, 28, 9-17.	0.8	18
43	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1814-1822.	2.0	18
44	CD34+ cell dose effects on clinical outcomes after cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2020, 95, 892-899.	4.1	18
45	The Circular Life of Human CD38: From Basic Science to Clinics and Back. <i>Molecules</i> , 2020, 25, 4844.	3.8	17
46	CXCR-4 Expression on Bone Marrow CD34+Cells Prior to Mobilization Can Predict Mobilization Adequacy in Patients with Hematologic Malignancies. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2003, 12, 425-434.	1.8	16
47	Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. <i>British Journal of Haematology</i> , 2016, 172, 111-121.	2.5	16
48	Prognostic Value of Immunophenotypic Characteristics of Blast Cells in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 13, 81-85.	1.3	15
49	Long-acting granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 757-772.	3.1	15
50	High-dose chemotherapy for germ cell tumors: do we have a model?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 33-44.	3.1	15
51	Single platform enumeration of viable CD34(pos) cells. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2003, 17, 247-53.	0.7	15
52	PCR with degenerate primers for highly conserved DNA polymerase gene of the herpesvirus family shows neither human herpesvirus 8 nor a related variant in bone marrow stromal cells from multiple myeloma patients. , 2000, 86, 76-82.		14
53	Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1505-1515.	3.1	14
54	Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 244.e1-244.e8.	1.2	14

#	ARTICLE	IF	CITATIONS
55	Cytochemically unreactive neutrophils from subjects with myeloperoxidase (MPO) deficiency show a complex pattern of immunoreactivity with anti-MPO monoclonal antibodies: A flow cytometric and immunocytochemical study. <i>Annals of Hematology</i> , 1991, 63, 94-100.	1.8	13
56	Cytogenetic and molecular cytogenetic profile of bone marrow-derived mesenchymal stromal cells in chronic and acute lymphoproliferative disorders. <i>Annals of Hematology</i> , 2012, 91, 1563-1577.	1.8	13
57	Plerixafor: what we still have to learn. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 143-147.	3.1	13
58	High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 70-75.	2.1	13
59	Manipulation, and cryopreservation of autologous peripheral blood stem cell products in Italy: A survey by GITMO, SIDEM and GIIMA societies. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102753.	1.0	12
60	Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Clinical Hematology International</i> , 2019, 1, 85-93.	1.7	12
61	Umbilical cord blood CD34+cell-derived progeny produces human leukocyte antigen-G molecules with immuno-modulatory functions. <i>Human Immunology</i> , 2012, 73, 150-155.	2.4	11
62	Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. <i>Cells</i> , 2020, 9, 2666.	4.1	11
63	Evaluation of CR1 expression in neutrophils from chronic myeloid leukaemia: relationship between prognosis and cellular activity. <i>British Journal of Haematology</i> , 1991, 77, 66-72.	2.5	10
64	CD34+ Leukemic Cells Assessed by Different CD:34 Monoclonal Antibodies. <i>Leukemia and Lymphoma</i> , 1995, 18, 25-30.	1.3	10
65	A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. <i>American Journal of Hematology</i> , 2017, 92, E557-E559.	4.1	10
66	NEW HORIZONS ON STEM CELL CRYOPRESERVATION THROUGH THE ARTIFICIAL EYES OF CD 34+, USING MODERN FLOW CYTOMETRY TOOLS. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102785.	1.0	10
67	COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: an Italian multicentre survey. <i>British Journal of Haematology</i> , 2021, 194, 854-856.	2.5	10
68	Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. <i>Cancers</i> , 2021, 13, 4566.	3.7	10
69	Darbepoetin 500 mcg Q3W, Alone or in Combination with Peg-Filgrastim, in Low/Int1 IPSS Risk Myelodysplastic Syndromes Unresponsive to Recombinant Erythropoietin.. <i>Blood</i> , 2007, 110, 4606-4606.	1.4	10
70	Photomultiplier voltage setting: Possible important source of variability in molecular equivalents of soluble fluorochrome (MESF) calculation?. <i>Cytometry</i> , 1995, 20, 362-368.	1.8	8
71	Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders. <i>Clinical Hematology International</i> , 2021, 3, 77.	1.7	8
72	Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 1876-1887.	2.4	8

#	ARTICLE	IF	CITATIONS
73	Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2022, 57, 1556-1563.	2.4	8
74	Complement Receptor 1 (CR1) Expression in Chronic Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 8, 35-41.	1.3	7
75	Letters to the editor. <i>Cytometry</i> , 1996, 24, 292-295.	1.8	7
76	Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 501-506.	2.0	7
77	High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 475-481.	2.0	7
78	An Overview of Current Position on Cell Therapy in Transfusion Science and Medicine: From Fictional Promises to Factual and Perspectives from Red Cell Substitution to Stem Cell Therapy. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102940.	1.0	6
79	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. <i>Biomedicines</i> , 2021, 9, 388.	3.2	6
80	In vitro assessment of bone marrow endothelial colonies (CFU-En) in non-Hodgkin's lymphoma patients undergoing peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 1165-1173.	2.4	5
81	Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 247-256.	1.5	5
82	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2018, 53, 722-728.	2.4	5
83	Issue Highlight "July 2018. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 557-560.	1.5	5
84	Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102941.	1.0	5
85	Issue Highlights "January 2013. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 1-4.	1.5	4
86	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. <i>Minerva Medica</i> , 2020, 111, 478-490.	0.9	4
87	Reduced expression of macrophage-associated antigens on alveolar mononuclear phagocytes from acquired immunodeficiency syndrome. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 146-150.	1.0	3
88	Adverse Haematological Effects of Ticlopidine. <i>Clinical Drug Investigation</i> , 2000, 19, 231-237.	2.2	3
89	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 163-167.	1.9	3
90	Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103105.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions. <i>Cancers</i> , 2021, 13, 4698.	3.7	3
92	Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells. <i>Cytometry</i> , 1997, 30, 134-44.	1.8	3
93	Immunosuppressive Properties of Mesenchymal Stromal Cells. , 2012, , 281-301.		2
94	An unusual association of paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, and diffuse large B-cell non-Hodgkin lymphoma in a Caucasian man. <i>Annals of Hematology</i> , 2016, 95, 1555-1557.	1.8	2
95	ISSUE HIGHLIGHTS â€•July 2020. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 295-298.	1.5	2
96	Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103499.	1.0	2
97	Analysis of the contemporary use of high-dose chemotherapy (HDCT) in germ cell tumors (GCT) in Europe: Early findings of an ongoing EBMT-sponsored study.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15536-e15536.	1.6	1
98	Towards standardization in immunophenotyping hematological malignancies. How can we improve the reproducibility and comparability of flow cytometric results? Working Group on Leukemia Immunophenotyping. <i>European Journal of Histochemistry</i> , 1996, 40 Suppl 1, 7-14.	1.5	1
99	Autologous stem cell transplantation: is it still relevant in breast cancer?. <i>Breast Cancer Management</i> , 2013, 2, 447-450.	0.2	0
100	Quality assessment of autologous haematopoietic blood progenitor cell grafting. <i>Annals of Hematology</i> , 2015, 94, 705-706.	1.8	0
101	Luigi Del Vecchio 1955â€“2018. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 181-182.	1.5	0
102	Acquired and Inherited Forms of Myeloperoxidase Deficiency: Clinical and Hematological Features. , 2000, , 150-156.		0
103	Moving towards the definition of new clusters of designation at the 6th International Workshop on Human Leukocyte Differentiation Antigens. A brief description of the recently clustered molecules. <i>European Journal of Histochemistry</i> , 1996, 40 Suppl 1, 63-74.	1.5	0